Display options
Cite
Mostafa E, Khatab A, Al-Adwy ER, et al. Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer. J Egypt Natl Canc Inst. 2007;19(1):28-38
Mostafa, E., Khatab, A., Al-Adwy, E. R., & Al-Assal, G. M. (2007). Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer. Journal of the Egyptian National Cancer Institute, 19(1), 28-38.
Mostafa, Ehab, et al. "Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer." Journal of the Egyptian National Cancer Institute vol. 19,1 (2007): 28-38.
Mostafa E, Khatab A, Al-Adwy ER, Al-Assal GM. Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer. J Egypt Natl Canc Inst. 2007 Mar;19(1):28-38. PMID: 18839033.
Copy Download .nbib Format: NLM
Share it on

J Egypt Natl Canc Inst. 2007 Mar;19(1):28-38.

Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer.

Journal of the Egyptian National Cancer Institute

Ehab Mostafa, Adel Khatab, Eman R Al-Adwy, Gihan M Al-Assal

Affiliations

  1. The Departments of Radiation Oncology&Nuclear Medicine, Ain Shams University.

PMID: 18839033

Abstract

PURPOSE: To evaluate the efficacy and outcome of concomitant cisplatin/etoposide and limited field irradiation followed by consolidation docetaxel in patients with locally advanced non small cell lung cancer (NSCLC).

PATIENTS AND METHODS: This is a prospective phase II study that included 32 patients with locally advanced stage III NSCLC who presented to the Radiation Oncology and Chest Departments- Ain Shams University hospitals, and Sohag Cancer Center between May 2004 and August 2006. Eligible patients were treated first with two cycles of cisplatin 50mg/m2/day on days 1, 8, 29 and 36 and etoposide 50mg/m2/day on days 1-5 and 29-33 concomitant with conventionally fractionated radiation (66Gy in 2Gy fractions) to the gross primary disease and regionally involved lymph nodes followed by 3 cycles of consolidation single agent docetaxel, 75mg/m2/3 weeks.

RESULTS: The median follow-up duration was 13.5 months (range from 6 to 30 months). The median survival was 17.4 months and the median progression free survival was 13 months. A total of 20 patients (62.5%) had treatment failure, 47% had an in field failure, 44% had distant failure, and one patient (3%) had isolated nodal failure (INF). Neutropenia (15.5%), anemia (19%), nausea and vomiting (15.5), esophagitis (9%) and pneumonitis (3%) were the most severe, grade 3 and 4, acute toxicities recorded during concomitant chemoradiation and 3 patients (9%) had grade 3 late esophagitis. Neutropenia (35%) and anemia (17%) were the most pronounced, grade 3 and 4, toxicities during consolidation chemotherapy.

CONCLUSION: Concomitant chemoradiation, without elective nodal irradiation (ENI), is a promising approach for management of locally advanced NSCLC. Conformal irradiation with possible dose escalation may provide an opportunity for more improvement of the therapeutic ratio. The addition of consolidation docetaxel is still questionable and needs more investigation. Key Words: NSCLC , Radiation , Cisplatin , Etoposide , Docetaxel.

Publication Types